Trial Profile
Clinical Trials Insight: 700036011
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2008
Price :
$35
*
At a glance
- Drugs Zonisamide/olanzapine (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Orexigen Therapeutics [CEASED]
- 13 Oct 2008 Status changed from planning to recruiting.
- 07 Aug 2008 New trial record.